EUDAMED Penalties: What Are the Risks of Non-Compliance Under the MDR?

Picture of Maurice Bagot D'arc

Maurice Bagot D'arc

ENT surgeon, head and neck surgeon, specialized in ENT oncology, legal compensation for bodily injury, and pharmaceutical marketing, with over 30 years of experience in Medical Affairs serving the healthcare industries and 15 years of surgical practice.

The progressive implementation of the European database EUDAMED marks a major milestone in the application of the European Union Medical Device Regulation (MDR 2017/745).

While many manufacturers are focusing on registration and reporting obligations, one critical issue remains largely underestimated: EUDAMED penalties and the consequences of non-compliance.

Beyond being a simple transparency platform, EUDAMED is part of a highly demanding regulatory framework that may lead to significant consequences for medical device manufacturers and economic operators.

EUDAMED Penalties: A Regulatory Framework That Must Be Followed

EUDAMED centralizes information relating to:

  • Economic operators
  • Medical devices and UDI registration
  • Certificates
  • Vigilance and market surveillance activities

Its objective is clear: improve traceability and transparency for medical devices across Europe.

The use of EUDAMED modules becomes mandatory from May 28, 2026. In practice, poor management of regulatory obligations can quickly expose manufacturers to EUDAMED penalties, even if these consequences are not always immediate or directly defined within the MDR itself.

Official references:

What Obligations Must Be Met to Avoid EUDAMED Penalties?

Manufacturers, authorized representatives, importers, and other economic operators must notably:

  • Register as economic operators
  • Register medical devices and UDIs
  • Maintain information up to date
  • Report incidents and corrective actions

Failure to comply with these obligations may directly expose companies to EUDAMED penalties that can go far beyond a simple warning letter.

What Are the Practical Consequences for Manufacturers?

Contrary to common assumptions, there is no single penalty applicable to all situations. EUDAMED penalties are defined and enforced at Member State level, but they can still be severe.

1. Market Access Suspension or Withdrawal

A non-compliant device may be:

  • Refused market access
  • Suspended from commercialization
  • Withdrawn from the market

This is often the most immediate and critical consequence for manufacturers.

2. MDR Audit Non-Conformities

Notified Bodies increasingly integrate EUDAMED compliance into their MDR audits and assessments.

Poor EUDAMED management may lead to:

  • Major non-conformities
  • Certification delays
  • Operational disruptions

For manufacturers already facing MDR transition pressures, these issues can have significant business impacts.

3. Financial Penalties and Administrative Sanctions

One of the most underestimated aspects of EUDAMED penalties is the possibility of financial sanctions.

Although the MDR does not define a harmonized EU-wide fine system, it requires Member States to establish:

  • Effective sanctions
  • Proportionate sanctions
  • Dissuasive sanctions

These measures may include administrative fines depending on national legislation.

In practice, consequences may involve:

  • Financial penalties
  • Administrative sanctions
  • Restrictions on commercial activities

These penalties are often linked to broader MDR non-compliance, of which EUDAMED obligations form an integral part.

4. Legal Risks and Manufacturer Liability

Poor management of EUDAMED vigilance obligations may also:

  • Delay incident reporting
  • Increase litigation risks
  • Trigger manufacturer liability issues

This is particularly critical in the context of post-market surveillance and vigilance reporting under the MDR.

Why EUDAMED Penalties Are Often Underestimated

Many manufacturers still perceive EUDAMED as a purely administrative requirement.

In reality, EUDAMED has become a central component of the European regulatory ecosystem, directly impacting:

  • Regulatory compliance
  • Market access
  • Corporate credibility

EUDAMED penalties are not always immediate, but they can become cumulative and highly damaging over time.

Real Examples of EUDAMED Penalties in Europe

In practice, EUDAMED penalties are not merely theoretical.

Several Competent Authorities across Europe have already intensified their inspections under MDR 2017/745, particularly regarding device traceability and data transparency.

Inspections have identified issues such as:

  • Devices marketed without complete EUDAMED registration
  • Incomplete or outdated information
  • Delays in incident reporting

These situations have resulted in:

  • Immediate corrective action requests
  • Temporary commercialization suspensions
  • Financial penalties imposed at national level

These examples illustrate a clear trend: EUDAMED penalties are becoming increasingly operational as authorities strengthen enforcement activities and gain experience with the system.

Conclusion: Anticipating EUDAMED Penalties Now

EUDAMED penalties are not limited to technical or administrative measures.

They may include:

  • Market restrictions
  • Regulatory blocking situations
  • Financial sanctions

In an increasingly demanding regulatory environment, EUDAMED must now be considered a strategic component of a manufacturer’s quality and compliance system.

Anticipating these obligations not only helps avoid EUDAMED penalties but also secures long-term access to the European medical device market.

If you would like to receive regularly our articles, please subscribe here

Other articles to consult

Participez au webinaire

Présentation de BluePharm Academy : Les modules de formation de BluePharm